ANDA 75577, held by Pharmobedient. Fluoxetine Hydrochloride.
As of Nov 16, 2026, ANDA 75577 (Fluoxetine Hydrochloride), held by Pharmobedient, was first approved by FDA on Jan 29, 2002, with 10 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 29, 2002 | Original application | Approved |
| Fluoxetine HydrochlorideEQ 10MG BASE · capsule;oral | Fluoxetine Hydrochloride | Discontinued |
| Fluoxetine HydrochlorideEQ 20MG BASE · capsule;oral | Fluoxetine Hydrochloride | Discontinued |
| Jun 12, 2024 | Supplement 15Labeling · Standard review | Approved | None posted |
| Jun 12, 2024 | Supplement 14Labeling · Standard review | Approved | None posted |
| Jul 6, 2009 | Supplement 11Labeling | Approved | None posted |
| Oct 8, 2008 | Supplement 10Labeling | Approved | None posted |
| Apr 17, 2008 | Supplement 9Labeling | Approved | None posted |
| Sep 12, 2007 | Supplement 8Labeling | Approved | None posted |
| Sep 12, 2007 | Supplement 7Labeling | Approved | None posted |
| Feb 28, 2006 | Supplement 6Labeling | Approved | None posted |
| May 17, 2005 | Supplement 4Labeling | Approved | None posted |
| May 17, 2005 | Supplement 3Labeling | Approved | None posted |
| Jan 29, 2002 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters